Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
Antengene presented latest preclinical data of ATG-201 at the 2025 American College of Rheumatology (ACR) Annual Meeting.
ATG-201 is a novel CD19-targeted T-cell engager developed on the AnTenGager™ TCE platform.
ATG-201 demonstrated potent efficacy in depleting B cells with reduced cytokine release, showing potential for treating autoimmune diseases and hematological malignancies.
ATG-201 is poised to enter clinical development in Q4 2025.